SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Stroke
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject12/6/2001 12:15:18 PM
From: nigel bates  Read Replies (1) of 70
 
Boehringer Ingelheim's Cerestat (aptiganel) has failed to demonstrate a therapeutic effect in patients with ischemic stroke. The results of a high-powered study, published in Wednesday's Journal of the American Medical Association, is yet another example of a failure from the cadre of developmental compounds dubbed "neuroprotective medicines" in the management of stroke. These agents derive from various classes of medicines that have demonstrated clinical utility in non-stroke neurological disease, including glutamate antagonists, calcium antagonists, opiate antagonists, kinase inhibitors, and antioxidants. In stroke care, neuroprotective drugs are designed to interfere with biochemical and electrical chains of events that occur in the several hours after an ischemic stroke (the most common form of stroke, which is caused by impaired blood flow leading to brain tissue oxygen deprivation). Cerestat joins Bristol-Myers Squibb's (NYSE: BMY) Maxipost and AstraZeneca's (NYSE: AZN) clomethiazole formulation as the most highly touted neuroprotective clinical failures.
Neuroprotective medicines are promising due to extraordinarily provocative data generated by animal studies. During an ischemic stroke, oxygen-deprived brain cells release large amounts of chemicals that permit calcium to enter and destroy nerve cells. Cerestat and other neuroprotective drugs reduce this sort of brain damage by up to 70% in a variety of animal models of stroke when given up to an hour after stroke onset...

(from today's bio.com)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News